To determine whether Lm-LLO-CD105A can disrupt RCC-associated tumor vasculature, the expression of vascular endothelium-specific proteins CD31 and VEGFR2 was analyzed in tumors from Lm-LLO-CD105A-treated mice (39). Here, PECAM1 is linked to neoplasm.